-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The US FDA will make a decision on Biogen's aducanumab on June 7.
And if rejected, it may have a profound impact on the Massachusetts-based company.
Analyst Iuri Struta said in the study that Biogen lacks preparation for the patent cliffs of the three key multiple sclerosis drugs Tysabri, Tecfidera and Vumerity.
At the same time, sales data show that the company's sales are declining rapidly.
According to Struta, aducanumab is "the only real hope to avoid falling into the patent cliff.
Insightia said that apart from these efforts, Bojian does not have enough measures to maintain sales before 2024.
Insightia pointed out that since Vounatsos took over in 2017, Bojian has only made one acquisition, that is, the acquisition of Nightstar Therapeutics for US$800 million.
It is not the first time for Bojian that activist investors have put pressure on the company.
Before the FDA made a decision on aducanumab, Brian Abrahams of RBC Capital Markets has warned investors to be prepared, not only for substantial changes in Bojian’s stock, but also for other sales.
Abrahams pointed out, “The FDA’s upcoming decision on aducanumab is not only critical for Bojian, but may also have repercussions in the entire biopharmaceutical field, affecting the overall sentiment in the field, regulatory flexibility, and business development dynamics.
Finishing: Zhilin-Acorn
